AstraZeneca has unveiled late-stage data backing use of its triple combination therapy PT010 in patients with chronic obstructive pulmonary disease (COPD).
Vertex Pharmaceuticals will begin testing a combination of VX-445, tezacaftor and ivacaftor as a potential treatment for people with cystic fibrosis (CF) in two Phase III studies.
GlaxoSmithKline has filed with the European Medicines Agency its Innoviva-partnered, once-daily, closed triple combination therapy as a treatment for patients with chronic obstructive pulmonary disease (COPD).